CompletedPhase 2NCT05569759

A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

Studying Autoimmune hepatitis

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Kezar Life Sciences, Inc.
Principal Investigator: Craig Lammert, MD
Indiana University
Intervention: zetomipzomib(drug)
Enrollment: 24 enrolled
Eligibility: 18 years · All sexes
Timeline: 2023 – 2025

Study locations (24)

Mayo Clinic Arizona, Phoenix, Arizona, United States
Keck School of Medicine of USC, Los Angeles, California, United States
University of California, Los Angeles, Los Angeles, California, United States
Stanford Medicine, Redwood City, California, United States
California Pacific Medical Center, San Francisco, California, United States
University of California, San Francisco, San Francisco, California, United States
University of Colorado, Aurora, Colorado, United States
Yale University, New Haven, Connecticut, United States
Mayo Clinic Florida, Jacksonville, Florida, United States
University of Miami, Miami, Florida, United States
Northwestern University, Chicago, Illinois, United States
Rush University, Chicago, Illinois, United States
Indiana University, Indianapolis, Indiana, United States
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
+9 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05569759 on ClinicalTrials.gov

Other trials for Autoimmune hepatitis

Additional recruiting or active studies for the same condition.

See all trials for Autoimmune hepatitis →

← Back to all trials